Replies to post #202104 on Biotech Values

[biomaven0]

I think today was a bargain day for any long-term biotech buyers.

I'm assuming the Visium HF collapse has had quite a lot to do with recent sector weakness. For example they held 2.3 million shares in FGEN - next report I bet we see that as close to zero.

Definitely think PRTK has good risk reward here - decent chance someone buys them.

The ability to seamlessly switch from IV to oral is significant.

Peter

[DewDiligence]

PRTK sells 4.9M* shares @$13.00—a 21% discount to Monday’s closing price:

http://finance.yahoo.com/news/paratek-announces-pricing-public-offering-120000836.html

*Assuming exercise of underwriter’s option.